Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05481736 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
A Phase 2 study, sponsored by COMPASS Pathways.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT05481736 is a Phase 2 study that has completed, run by COMPASS Pathways. The registered enrollment target is 32 participants.
The verdict
NCT05481736, a Phase 2 study, has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2024-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05481736
The ClinicalTrials.gov registry entry for NCT05481736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT05481736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05481736 about?
NCT05481736 is a clinical study titled "Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study". Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study
What is the current status of trial NCT05481736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-10-12. Estimated completion is 2024-11-18.
What interventions are being tested in trial NCT05481736?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05481736?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.